UPDATE – Video archive now available for viewing!Next Monday night, 8 PM EST, on my Ticker.tv channel StockJunkie, I am going to have the pleasure of interviewing Ross Cameron of DayTradeWarrior.com.When someone referred me to Ross Cameron’s year end results for 2014, I immediately took an interest. From his blog post, Ross finished the year with a total profit of […]
SummaryThere are many types of risk associated with investing.
Some risks are obvious and straightforward while other risks are far less obvious.
One of the most obvious risks is valuation risk.
As we enter 2015 with a blended P/E ratio of 17, the S&P 500’s valuation sits at the upper end of its historical normal valuation range since 2001.
Current S&P 500 valuation suggests […]
Quick note – Please take our quarterly reader survey here; just 3 quick questions to help us continue to serve you. Thanks!Watch tonight’s video market recap on my Ticker.tv channel, Mark333.Indexes had a decent bounce back day as oil finally stopped its relentless drop and some news in the housing sector helped to lift spirits. In Europe, Germany left open […]
Sovaldi pill. Source: Gilead SciencesGilead Sciences had another phenomenal year in 2014, returning 26% for investors. That’s more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank.In just the first nine months of 2014, Sovaldi netted Gilead $8.55 billion in sales. It’s the most effective drug launch in history by […]
Benchmarks dropped sharply on Monday with energy shares leading the decline due to another slump in oil prices. An increase in production of oil and strengthening of the dollar were responsible for dragging oil prices to its lowest level since 2009. Renewed political unrest in Greece that may result in a possible departure of the country from Eurozone also dampened […]
SAN FRANCISCO (MarketWatch) — Cyberonics Inc. shares declined in the extended session Monday after the medical device maker said its appeal of a medical reimbursement decision was denied.Cyberonics CYBX, +5.49% shares fell 8.1% to $53.10 on moderate volume after an appeals board supported a 2007 decision by the Centers for Medicare and Medicaid that the company’s pacemaker-like device for treating […]
Read More Why stocks ‘more vulnerable’ in 2015: PaulsenIt might be tempting to try something new altogether, but Sam Stovall of S&P Capital IQ says in a report that one of the best sectors of 2014 is looking good again. The health-care sector has jumped more than 23% during 2014 — making it one of the best places for stocks.And […]
Source: GlaxoSmithKline via Flickr.When it comes to healthcare events, there is none more important than the JPMorgan Healthcare Conference. Filled with dozens upon dozens of biotech and medical device companies, the JPMorgan Healthcare Conference, coming up in mid-January, is the perfect time for companies to unveil a study or device they’ve been keeping under their thumb for a rainy day.With […]
Over the last several years, there has rarely been a bad time to own biotechnology exchange traded funds. That much is confirmed by the presence of multiple biotech ETFs on the annual lists of the top 10 sector funds.In 2014, each of the five major biotech ETFs ranked among the year’s top 10 sector ETFs. That includes the First Trust […]
SummaryThe powerful rallies of 2013 and 2014 were driven by extreme Fed money printing to buy up bonds, and the Fed’s associated implied backstop for the stock markets.
But with QE3’s new buying terminated and any QE4 a political impossibility with the new Republican Congress, 2015 is going to look vastly different without QE.
With the Fed’s balance sheet and zeroed interest […]
